Regeneron Gets Appeals Court to Impose Tougher Kickback Standard
Regeneron Pharmaceuticals Inc. convinced the First Circuit to impose a higher causation standard in the government’s False Claims Act case alleging a drug kickback scheme, according to a Tuesday ...
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
PharmiWeb18h
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).
Press Release: Dupixent Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...
Long Island Press1d
Herricks school district holds first budget meeting, celebrates Regeneron scholars
Herricks School District held its first budget meeting of the year last Thursday. The district’s Board of Education estimated ...
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / February 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
PipelineReview.com6d
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
About the Linvoseltamab Clinical Development Program Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with ...